NCT05773040 2025-11-10
A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas
M.D. Anderson Cancer Center
Phase 1 Recruiting
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Hebei Senlang Biotechnology Inc., Ltd.
Mayo Clinic
Washington University School of Medicine